<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768829</url>
  </required_header>
  <id_info>
    <org_study_id>S85Motic</org_study_id>
    <nct_id>NCT04768829</nct_id>
  </id_info>
  <brief_title>Antifungal Potential of Moringa Olifera Against Otomycosis</brief_title>
  <official_title>Antifungal Potential of Moringa Olifera-loaded Nanoparticles Against Otomycosis; Preparation, Characterization, and Clinical Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deraya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deraya University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      patients with Otomycosis were recognized by an ENT specialist. 20 patients were distributed&#xD;
      randomly into two groups. The first group will be treated with Nystatin ear drops twice&#xD;
      daily. The second group will be treated with Moringa ear drops. patients will be examined&#xD;
      endoscopically by the ENT specialist. patient's swabs will be isolated and analyzed by ELISA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
      (1) Otomycosis .&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. tympanic membrane perforation;&#xD;
&#xD;
        2. concurrent immune suppression,&#xD;
&#xD;
        3. and concurrent bacterial infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>moringa extract ear drops</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants recovered with clear endoscopic examination</measure>
    <time_frame>one week</time_frame>
    <description>Number of participants recovered with clear endoscopic examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of different microorganisms infected ear</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Patients swabs (microorganisms concentration)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moringa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moringa oleifera leaf 10mg/100ml</intervention_name>
    <description>ear drops</description>
    <arm_group_label>Moringa group</arm_group_label>
    <other_name>ear drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ear Drop</intervention_name>
    <description>plain ear drop formulation without moringa</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Otomycosis&#xD;
&#xD;
          2. ear inflammation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. tympanic membrane perforation&#xD;
&#xD;
          2. concurrent immune suppression,&#xD;
&#xD;
          3. concurrent bacterial infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soad A Mohamad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deraya University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soad A. Mohamad</name>
      <address>
        <city>Minya</city>
        <state>المنيا</state>
        <zip>05673</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Deraya University</investigator_affiliation>
    <investigator_full_name>Soad Ali</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamide Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>publication in peer-reviewed journals</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

